Get the tools used by (smart)2 investors.

Nektar TherapeuticsNASDAQCM:NKTR

United States / Healthcare / Pharmaceuticals

Join now and get access to the full platform

Exchange Data

Hide this widget
0.74 USD
Price
0.05 (7.29%)
Day change
0.43 - 1.93
52-week range

Summary of Nektar Therapeutics

Hide this widget

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat...

Filings

Price History

Chart Gallery
Hide this widget
- (-)
Mar 25Mar 29Apr 3Apr 7Apr 12Apr 17Apr 250.500.600.700.80

Data Explorer

Peer Benchmarks

Hide this widget
  NKTR Peers Sector
Market Cap
137.4 M1.689 B64.892 M
Price % of 52 Week High
38.3%64.8%62.4%
Dividend Yield
0.0%0.0%0.0%
Shareholder Yield
28.3%0.6%-0.7%
1 Year Price Total Return
-44.1%0.4%-11.7%
Beta (5 Year)
0.690.910.64

Finbox Fair Value

Hide this widget
What is Finbox Fair Value?
A stock's fair value is its real or underlying intrinsic worth.
Read more about Finbox's Fair Value methodology.
USD
Average
Upside
Uncertainty
You need an account to use this feature
Sign Up
Or
Log In

Financial Health

Financial Models for Nektar Therapeutics

Model Gallery
Hide this widget

Historical Financials

Full Financials
Hide this widget
(presentment in millions)Trailing Twelve MonthsFiscal Quarters
Period EndingDec-22Dec-23Dec-24Dec-23Dec-24
Income Statement
Revenue9290982429
Operating Income(240)(135)(130)(31)(25)
Net Profit(368)(276)(119)(42)7.26
Diluted EPS-1.97-1.45-0.58-0.220.034
EBITDA(227)(127)(126)(29)(24)
Balance Sheet
Cash & ST Invest.505304255304255
Current Assets546331261331261
Total Assets711398304398304
Current Liabilities6851615161
Total Liabilities344267243267243
Total Equity3671316113161
Total Debt287230194230194
Cash Flow Statement
Cash Flow Operations(304)(193)(176)(47)(46)
Cash From Investing3661401431760
Cash From Financing1.510.03420.010.08
Free Cash Flow(310)(193)(177)(47)(47)

Analyst Notes

April 25, 2025
Hide this widget
    All rights reserved. Terms Of Use